Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 3/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20545877 | 1.00 | CTSA (0.47) | CTSAKMT2ASMN1; SMN2MMEMMP12 | |
| SCHEMBL20546119 | 0.86 | CTSA (0.53) | CTSAKMT2ASMN1; SMN2MMESLC13A5 | |
| SCHEMBL30671437 | 0.86 | POLB (0.41) | CTSAKMT2ASMN1; SMN2MME | |
| SCHEMBL20546118 | 0.86 | CTSA (0.53) | CTSAKMT2ASMN1; SMN2MMESLC13A5 | |
| SCHEMBL28372538 | 0.86 | POLB (0.41) | CTSAKMT2ASMN1; SMN2MME | |
| SCHEMBL20546028 | 0.85 | CTSA (0.61) | CTSAKMT2ASMN1; SMN2MMESLC13A5 | |
| SCHEMBL20546029 | 0.85 | CTSA (0.61) | CTSAKMT2ASMN1; SMN2MMESLC13A5 | |
| SCHEMBL20545899 | 0.84 | CTSA (0.64) | CTSAKMT2ASMN1; SMN2MMESLC13A5 | |
| SCHEMBL20545894 | 0.84 | CTSA (0.52) | CTSAKMT2ASMN1; SMN2MMEMMP12 | |
| SCHEMBL20545896 | 0.84 | CTSA (0.52) | CTSAKMT2ASMN1; SMN2MMEMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-110914242-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3615514-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Aviara Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| WO-2018201167-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885KMT2A 4455/4885SMN1; SMN2 2021/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | CTSA 2240/4885KMT2A 4455/4885SMN1; SMN2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.